Stefani Spranger

Stefani Spranger

Howard S. and Linda B. Stern Career Development Assistant Professor

Stefani Spranger studies how the body’s immune system interacts with growing tumors to harness the immune response to fight cancer.

617-715-5882

Phone

76-453D

Office

Paul Thompson

Assistant

617-258-0480

Assistant Phone

Education

  • PhD, 2011, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • MSc, Biology, 2008, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich
  • BSc, Biology, 2005, Ludwig-Maximilian University Munich/Helmholtz-Zentrum Munich

Research Summary

We examine the interaction between cancer and immune cells. Using tumor mouse models designed to mimic tumor progression in humans, we investigate the co-evolution of the anti-tumor immune response and cancer. Understanding the interplay between tumor cells and immune cells will help develop and improve effective cancer immunotherapies.

Awards

  • Forbeck Fellow, 2015

Recent Publications

  1. Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cohen, MA, Zhang, S, Sengupta, S, Ma, H, Bell, GW, Horton, B, Sharma, B, George, RE, Spranger, S, Jaenisch, R et al.. 2020. Cell Stem Cell , .
    doi: 10.1016/j.stem.2020.02.001PMID:32142683
  2. CD36 - the Achilles' heel of Treg cells. Horton, BL, Spranger, S. 2020. Nat. Immunol. 21, 251-253.
    doi: 10.1038/s41590-020-0601-0PMID:32066948
  3. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling. Nguyen, KB, Spranger, S. 2020. J. Cell Biol. 219, .
    doi: 10.1083/jcb.201908224PMID:31816057
  4. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). Ascierto, PA, Bifulco, C, Buonaguro, L, Emens, LA, Ferris, RL, Fox, BA, Delgoffe, GM, Galon, J, Gridelli, C, Merlano, M et al.. 2019. J Immunother Cancer 7, 332.
    doi: 10.1186/s40425-019-0798-3PMID:31783779
  5. Tissue Site and the Cancer Immunity Cycle. Horton, BL, Fessenden, TB, Spranger, S. 2019. Trends Cancer 5, 593-603.
    doi: 10.1016/j.trecan.2019.07.006PMID:31706507
  6. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. Trujillo, JA, Luke, JJ, Zha, Y, Segal, JP, Ritterhouse, LL, Spranger, S, Matijevich, K, Gajewski, TF. 2019. J Immunother Cancer 7, 295.
    doi: 10.1186/s40425-019-0780-0PMID:31703593
  7. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 167.
    doi: 10.1186/s40425-019-0640-yPMID:31272507
  8. Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Momin, N, Mehta, NK, Bennett, NR, Ma, L, Palmeri, JR, Chinn, MM, Lutz, EA, Kang, B, Irvine, DJ, Spranger, S et al.. 2019. Sci Transl Med 11, .
    doi: 10.1126/scitranslmed.aaw2614PMID:31243150
  9. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. Bedognetti, D, Ceccarelli, M, Galluzzi, L, Lu, R, Palucka, K, Samayoa, J, Spranger, S, Warren, S, Wong, KK, Ziv, E et al.. 2019. J Immunother Cancer 7, 131.
    doi: 10.1186/s40425-019-0602-4PMID:31113486
  10. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Luke, JJ, Bao, R, Sweis, RF, Spranger, S, Gajewski, TF. 2019. Clin. Cancer Res. 25, 3074-3083.
    doi: 10.1158/1078-0432.CCR-18-1942PMID:30635339
More Publications

Multimedia

Photo credit: Kelsey Montgomery